Welcome to Hodoodo Chemicals

Rabeprazole sulfide
featured

WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H461117

CAS#: 117977-21-6

Description: Rabeprazole sulfide is an active metabolite of rabeprazole, a proton pump inhibitor.

Chemical Structure

Rabeprazole sulfide

CAS# 117977-21-6

Instruction

Theoretical Analysis

Hodoodo Cat#: H461117
Name: Rabeprazole sulfide
CAS#: 117977-21-6
Chemical Formula: C18H21N3O2S
Exact Mass: 343.14
Molecular Weight: 343.450
Elemental Analysis: C, 62.95; H, 6.16; N, 12.24; O, 9.32; S, 9.33

Price and Availability

Size	Price	Availability	Quantity
25mg	USD 1360	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. Hodoodo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Rabeprazole thioether; Rabeprazole impurity E; Rabeprazole sulfide

IUPAC/Chemical Name: 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)thio)-1H-benzo[d]imidazole

InChi Key: BSXAHDOWMOSVAP-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H21N3O2S/c1-13-16(19-9-8-17(13)23-11-5-10-22-2)12-24-18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)

SMILES Code: Cc1c(CSc([nH]2)nc3c2cccc3)nccc1OCCCOC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 343.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Lu C, Jia Y, Song Y, Li X, Sun Y, Zhao J, Wang S, Shi L, Wen A, Ding L. Application of a liquid chromatographic/tandem mass spectrometric method to a urinary excretion study of rabeprazole and two of its metabolites in healthy human urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Apr 15;988:75-80. doi: 10.1016/j.jchromb.2015.01.023. Epub 2015 Jan 23. PubMed PMID: 25755073.

2: Simpemba E, Liu R, Sun C, Agbokponto JE, Ding L. Simultaneous determination of rabeprazole and its two active metabolites in human urine by liquid chromatography with tandem mass spectrometry and its application in a urinary excretion study. J Sep Sci. 2014 Aug;37(15):1951-6. doi: 10.1002/jssc.201400162. Epub 2014 Jun 30. PubMed PMID: 24798930.

3: Miura M, Satoh S, Tada H, Habuchi T, Suzuki T. Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes. Eur J Clin Pharmacol. 2006 Feb;62(2):113-7. Epub 2005 Dec 31. PubMed PMID: 16389533.

4: Thyssen A, Solanki B, Treem W. Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension. Clin Ther. 2012 Jul;34(7):1636-45. doi: 10.1016/j.clinthera.2012.06.008. Epub 2012 Jun 29. PubMed PMID: 22748970.

5: Uno T, Yasui-Furukori N, Shimizu M, Sugawara K, Tateishi T. Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Sep 25;824(1-2):238-43. PubMed PMID: 16087412.

6: Uno T, Shimizu M, Yasui-Furukori N, Sugawara K, Tateishi T. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br J Clin Pharmacol. 2006 Mar;61(3):309-14. PubMed PMID: 16487224; PubMed Central PMCID: PMC1885025.

7: Miura M. Enantioselective disposition of lansoprazole and rabeprazole in human plasma. Yakugaku Zasshi. 2006 Jun;126(6):395-402. Review. PubMed PMID: 16755125.

8: Shimizu M, Uno T, Yasui-Furukori N, Sugawara K, Tateishi T. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603. Epub 2006 Jun 17. PubMed PMID: 16783561.

9: Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. PubMed PMID: 15258107.

10: Ren S, Park MJ, Kim A, Lee BJ. In vitro metabolic stability of moisture-sensitive rabeprazole in human liver microsomes and its modulation by pharmaceutical excipients. Arch Pharm Res. 2008 Mar;31(3):406-13. doi: 10.1007/s12272-001-1171-z. Epub 2008 Apr 13. PubMed PMID: 18409057.

11: Niioka T, Uno T, Yasui-Furukori N, Shimizu M, Sugawara K, Tateishi T. Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve. Eur J Clin Pharmacol. 2006 Oct;62(10):855-61. Epub 2006 Aug 17. PubMed PMID: 16915367.

12: Miura M, Tada H, Satoh S, Habuchi T, Suzuki T. Determination of rabeprazole enantiomers and their metabolites by high-performance liquid chromatography with solid-phase extraction. J Pharm Biomed Anal. 2006 May 3;41(2):565-70. Epub 2006 Jan 18. PubMed PMID: 16442771.

13: Lin CJ, Yang JC, Uang YS, Chern HD, Wang TH. Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. Pharmacotherapy. 2003 Jun;23(6):711-9. PubMed PMID: 12820812.

14: Ohbuchi M, Noguchi K, Kawamura A, Usui T. Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. Xenobiotica. 2012 Jul;42(7):633-40. doi: 10.3109/00498254.2011.653655. Epub 2012 Feb 7. PubMed PMID: 22313038.

Your view history

Rabeprazole sulfide featured